Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CELC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCELCCelcuity$107.95$112.70$13.13▼$151.02$5.26B0.161.29 million shs906,233 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCELCCelcuity+3.31%+12.53%+18.08%-4.16%+727.84%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCELCCelcuity$107.95$112.70$13.13▼$151.02$5.26B0.161.29 million shs906,233 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCELCCelcuity+3.31%+12.53%+18.08%-4.16%+727.84%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCELCCelcuity 2.83Moderate Buy$152.0940.89% UpsideCurrent Analyst Ratings BreakdownLatest CELC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/4/2026CELCCelcuity Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/3/2026CELCCelcuity Craig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$189.00 ➝ $171.006/3/2026CELCCelcuity GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/3/2026CELCCelcuity Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$183.00 ➝ $166.006/3/2026CELCCelcuity HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$185.00 ➝ $145.006/2/2026CELCCelcuity Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$155.005/28/2026CELCCelcuity Macquarie InfrastructureSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$160.005/28/2026CELCCelcuity CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform5/19/2026CELCCelcuity Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/18/2026CELCCelcuity HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$165.00 ➝ $185.00(Data available from 7/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCELCCelcuityN/AN/AN/AN/A$2.17 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCELCCelcuity-$177.04M-$3.90N/A719.67N/AN/A-244.61%-50.22%8/13/2026 (Estimated)Latest CELC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026CELCCelcuity-$1.07-$0.97+$0.10-$0.97$2.94 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCELCCelcuityN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCELCCelcuity6.0412.3112.31Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCELCCelcuity63.33%Insider OwnershipCompanyInsider OwnershipCELCCelcuity13.33%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCELCCelcuity4048.77 million42.27 millionOptionableCELC HeadlinesRecent News About These CompaniesCelcuity Inc.June 27, 2026 | marketwatch.comCelcuity, Inc. (NASDAQ:CELC) Receives Average Rating of "Moderate Buy" from BrokeragesJune 24, 2026 | americanbankingnews.comCapitolis Liquid Global Markets LLC Purchases Shares of 355,200 Celcuity, Inc. $CELCJune 18, 2026 | marketbeat.com63,415 Shares in Celcuity, Inc. $CELC Purchased by ACT Capital Management LLCJune 18, 2026 | marketbeat.comGranahan Investment Management LLC Purchases 37,751 Shares of Celcuity, Inc. $CELCJune 17, 2026 | marketbeat.comAvoro Capital Advisors LLC Takes Position in Celcuity, Inc. $CELCJune 17, 2026 | marketbeat.comAtom Investors LP Takes Position in Celcuity, Inc. $CELCJune 17, 2026 | marketbeat.comSofinnova Investments Inc. Has $29.86 Million Stock Holdings in Celcuity, Inc. $CELCJune 16, 2026 | marketbeat.comHealthcare of Ontario Pension Plan Trust Fund Buys Shares of 221,595 Celcuity, Inc. $CELCJune 16, 2026 | marketbeat.comCelcuity Inc. (CELC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 10, 2026 | seekingalpha.comTD Asset Management Inc Has $9.73 Million Stake in Celcuity, Inc. $CELCJune 10, 2026 | marketbeat.comGeode Capital Management LLC Purchases 64,213 Shares of Celcuity, Inc. $CELCJune 8, 2026 | marketbeat.comBNP Paribas Financial Markets Sells 36,648 Shares of Celcuity, Inc. $CELCJune 8, 2026 | marketbeat.comBI Asset Management Fondsmaeglerselskab A S Takes $5.10 Million Position in Celcuity, Inc. $CELCJune 8, 2026 | marketbeat.comHC Wainwright Has Negative Estimate for Celcuity Q3 EarningsJune 5, 2026 | marketbeat.comCelcuity Inc. (CELC) Discusses VIKTORIA-1 Trial Results for PIK3CA Mutant Advanced Breast Cancer and Gedatolisib Efficacy - SlideshowJune 4, 2026 | seekingalpha.comCelcuity slides even after ‘practice-changing’ late-stage breast cancer dataJune 4, 2026 | biospace.comBCelcuity (CELC) Expands Phase 3 VIKTORIA-2 Trial to Include Endocrine-Sensitive Breast Cancer PatientsJune 4, 2026 | finance.yahoo.comASCO26: Celcuity punished as trial disappoints investorsJune 4, 2026 | pharmaphorum.comPCelcuity (CELC) Weighs Dilution Against Drug Development After $500 Million Convertible Note OfferingJune 4, 2026 | finance.yahoo.comCelcuity shares fall despite strong phase 3 breast cancer trial data (CELC)June 4, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCELC Company DescriptionsCelcuity NASDAQ:CELC$107.95 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$105.87 -2.08 (-1.93%) As of 07/2/2026 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst SanDisk’s Volatility May Be Telling Bulls What They Want to Hear Why the Comcast Spin-Off Won't Fix What's Actually Broken Shorting the Grid: Bloom Energy’s $25B AI Power Play AST SpaceMobile’s Japan Catalyst Puts Its Rollout Story Back in Focus Why Kroger's Giant Eagle Deal Could Change Everything SMRs Spark a Chain Reaction for Nano Nuclear Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
